PART I. FINANCIAL INFORMATION [Item 1. Financial Statements](index=5&type=section&id=Item%201.%20Financial%20Statements) The company's unaudited condensed consolidated financial statements and notes detail its financial position, performance, cash flows, accounting policies, debt, and strategic alliances [Condensed Consolidated Financial Statements](index=6&type=section&id=Condensed%20Consolidated%20Financial%20Statements) The company's financial position reflects decreased total assets and revenues, a significantly widened net loss in Q2 2025, and increased cash used in operating activities Condensed Consolidated Balance Sheet Highlights (As of June 30, 2025) | Metric | June 30, 2025 ($ thousands) | December 31, 2024 ($ thousands) | | :--- | :--- | :--- | | Cash, cash equivalents and current restricted cash | 271,718 | 431,936 | | Total current assets | 583,333 | 662,089 | | Total assets | 1,972,989 | 2,200,212 | | Total current liabilities | 171,181 | 193,096 | | Total liabilities | 676,085 | 834,764 | | Total shareholders' equity | 1,296,904 | 1,365,448 | Condensed Consolidated Statement of Operations Highlights | Metric | Q2 2025 ($ thousands) | Q2 2024 ($ thousands) | H1 2025 ($ thousands) | H1 2024 ($ thousands) | | :--- | :--- | :--- | :--- | :--- | | Total revenues | 156,807 | 182,186 | 306,759 | 355,872 | | Operating loss | (59,981) | (61,670) | (127,148) | (133,143) | | Net loss | (148,441) | (10,305) | (216,054) | (92,141) | | Loss per share, basic and diluted | (0.19) | (0.01) | (0.31) | (0.13) | Condensed Consolidated Statement of Cash Flows Highlights (Six Months Ended June 30) | Metric | 2025 ($ thousands) | 2024 ($ thousands) | | :--- | :--- | :--- | | Net cash used in operating activities | (117,974) | (62,001) | | Net cash provided by (used in) investing activities | 37,694 | (11,557) | | Net cash (used in) provided by financing activities | (83,511) | 18,498 | | Net decrease in cash, cash equivalents and restricted cash | (160,220) | (55,305) | [Notes to Condensed Consolidated Financial Statements](index=12&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) Notes detail healthcare operations, oncology diagnostics sale, debt exchanges, strategic alliances, and a material tax assessment contingency - The company entered into an agreement with Labcorp to sell its oncology diagnostics business for up to **$225 million**, with the transaction expected to close in the second half of 2025, and these assets are now classified as held for sale[32](index=32&type=chunk)[33](index=33&type=chunk) - In April 2025, the company exchanged **$159.2 million** of its 2029 Convertible Notes for **121.4 million shares** of common stock and **$63.5 million** in cash, resulting in a total charge of **$91.7 million**[116](index=116&type=chunk) - The collaboration with BARDA was expanded, increasing the total contract value to **$110.0 million**, with a potential value of up to **$205 million** if all options are exercised, recognizing **$13.5 million** in revenue for H1 2025[187](index=187&type=chunk)[191](index=191&type=chunk) - A significant legal contingency exists with the Israel Tax Authority, which issued an assessment of approximately **$246 million** against a subsidiary, which the company is appealing[146](index=146&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=64&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses Q2 and H1 2025 financial results, highlighting revenue decline from divestitures, a widened net loss, and sufficient liquidity for the next 12 months [Results of Operations](index=65&type=section&id=Results%20of%20Operations) Q2 2025 consolidated revenues decreased **14%** due to Diagnostics divestitures, Pharmaceuticals revenue grew **6%**, and the net loss significantly widened primarily from increased interest expense Consolidated Results of Operations (Q2 2025 vs. Q2 2024) | Metric (in thousands) | Q2 2025 | Q2 2024 | Change | % Change | | :--- | :--- | :--- | :--- | :--- | | Total revenues | $156,807 | $182,186 | $(25,379) | (14)% | | Loss from operations | $(59,981) | $(61,670) | $1,689 | 3% | - Diagnostics segment revenue decreased by **21.9%** in Q2 2025, primarily due to the absence of revenue from lab operations sold to Labcorp in September 2024, though its operating loss improved by **32%** to **$18.2 million** due to cost reductions and divestiture[245](index=245&type=chunk) - Pharmaceuticals segment revenue increased by **6%** in Q2 2025, driven by a **22%** rise in intellectual property revenue from the BARDA contract and commercial milestones, but operating loss widened by **16%** to **$28.7 million** due to increased R&D expenses[252](index=252&type=chunk)[253](index=253&type=chunk) - Interest expense for Q2 2025 surged to **$70.3 million** from **$8.2 million** in Q2 2024, mainly due to the amortization of **$54.7 million** in unamortized debt discount and **$4.4 million** in debt issuance costs from the Note Exchange Transactions[261](index=261&type=chunk) [Liquidity and Capital Resources](index=76&type=section&id=Liquidity%20and%20Capital%20Resources) As of June 30, 2025, the company held **$285.4 million** in cash, with management deeming liquidity sufficient for over 12 months, supported by asset sales and potential milestones - The company held **$285.4 million** in cash, cash equivalents, and restricted cash as of June 30, 2025, with cash used in operations for H1 2025 at **$118.0 million**[291](index=291&type=chunk) - The company expects to receive up to **$225 million** in cash from the sale of its oncology business to Labcorp, expected to close in the second half of 2025[294](index=294&type=chunk) - Significant potential future cash inflows include up to **$860.0 million** in milestones from the Merck agreement and up to **$275.0 million** from the Pfizer agreement, in addition to tiered royalties[303](index=303&type=chunk)[304](index=304&type=chunk) Contractual Obligations as of June 30, 2025 (in thousands) | Obligation Type | Total | Due in < 1 Year | Due in 1-3 Years | Due in 3-5 Years | Due Thereafter | | :--- | :--- | :--- | :--- | :--- | :--- | | Debt (Notes, Mortgages, Lines of Credit) | $344,793 | $14,921 | $1,131 | $80,416 | $248,325 | | Operating & Finance Leases | $52,465 | $6,075 | $10,283 | $6,742 | $29,365 | | Open Purchase Orders | $32,740 | $27,366 | $5,374 | $0 | $0 | | Interest Commitments | $16,530 | $2,368 | $9,322 | $4,840 | $0 | [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=83&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company's primary market risks are foreign currency exchange rates, with **24.5%** of H1 2025 revenue in foreign currencies, and interest rates, managed through short-term investments - Foreign currency risk is significant, with **24.5%** of revenue in H1 2025 denominated in currencies other than the USD, primarily the Chilean Peso and Euro, mitigated by foreign exchange forward contracts[319](index=319&type=chunk)[322](index=322&type=chunk) - Interest rate risk exposure relates to **$285.4 million** in cash/investments and **$12.5 million** outstanding on variable-rate lines of credit, managed by maintaining short-term maturities for investments[323](index=323&type=chunk)[324](index=324&type=chunk) [Item 4. Controls and Procedures](index=84&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that the company's disclosure controls and procedures were effective as of June 30, 2025, with no material changes to internal control over financial reporting - Management concluded that the company's disclosure controls and procedures were effective as of the end of the period covered by the report[327](index=327&type=chunk) - There were no changes to the company's internal control over financial reporting during the quarter that materially affected, or are reasonably likely to materially affect, these controls[328](index=328&type=chunk) PART II. OTHER INFORMATION [Item 1. Legal Proceedings](index=84&type=section&id=Item%201.%20Legal%20Proceedings) This section details the company's legal matters, including an appeal against a **$246 million** tax assessment and a 5-year Corporate Integrity Agreement - The company is appealing a tax assessment of approximately **$246 million** issued by the Israel Tax Authority against its subsidiary, OPKO Biologics[146](index=146&type=chunk) - The company and its subsidiary BioReference are subject to a 5-year Corporate Integrity Agreement (CIA) with the OIG-HHS, effective July 2022, to resolve an investigation into past billing practices[147](index=147&type=chunk)[149](index=149&type=chunk) [Item 1A. Risk Factors](index=84&type=section&id=Item%201A.%20Risk%20Factors) The company reports no material changes to its risk factors from those previously disclosed in its Annual Report and Q1 2025 Form 10-Q - There have been no material changes to the company's risk factors from those previously disclosed[330](index=330&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=84&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) In Q2 2025, the company repurchased **13.6 million shares** for **$18.3 million** under a **$200 million** program, with **$141.5 million** remaining Share Repurchase Activity (Q2 2025) | Period | Total Shares Purchased | Average Price Paid per Share | Total Cost (approx.) | | :--- | :--- | :--- | :--- | | May 2025 | 9,646,344 | $1.31 | $12.6M | | June 2025 | 4,000,000 | $1.36 | $5.4M | | **Total Q2** | **13,646,344** | **$1.34** | **$18.3M** | - The stock repurchase program was increased by **$100.0 million** on April 4, 2025, bringing the total authorized amount to **$200 million**, with **$141.5 million** remaining available for repurchase as of June 30, 2025[331](index=331&type=chunk) [Other Disclosures (Items 3, 4, 5, 6)](index=84&type=section&id=Other%20Disclosures%20%28Items%203%2C%204%2C%205%2C%206%29) This section confirms standard corporate disclosures, including no defaults on senior securities, no mine safety disclosures, and no Rule 10b5-1 trading plan changes - The company reported no defaults upon senior securities[332](index=332&type=chunk) - No officers or directors adopted or terminated a Rule 10b5-1 trading plan during the quarter ended June 30, 2025[335](index=335&type=chunk)

[Business Highlights](index=1&type=section&id=Business%20Highlights) OPKO advanced its clinical pipeline, including a Phase 1 Epstein-Barr virus vaccine and immuno-oncology candidates, and received FDA approval for its 4Kscore® Test without DRE, expanding its utility - Merck advanced the Phase 1 trial for the Epstein-Barr virus vaccine candidate, with results expected to inform the decision on Phase 2 studies[1](index=1&type=chunk) - ModeX's immuno-oncology portfolio is advancing, with MDX2001 in Phase 1, MDX2004 expected to enter clinic later in 2025, and MDX2003 trials planned for early 2026[1](index=1&type=chunk) - Preclinical data for OPK-88006, a GLP-1/glucagon dual agonist, showed superior therapeutic benefits on MASH hallmarks compared to semaglutide and survodutide in a mouse model[1](index=1&type=chunk) - The FDA approved a supplemental application for the 4Kscore® Test, allowing its use without digital rectal examination (DRE) information, which is significant as over 90% of PSA screening tests are done by primary care providers who don't routinely perform DREs[4](index=4&type=chunk) - An abstract for an oral GLP-2 tablet for short bowel syndrome, developed with Entera Bio, was selected for presentation at the 2025 ESPEN Congress[4](index=4&type=chunk) [Financial Results](index=2&type=section&id=Financial%20Results) OPKO's Q2 2025 consolidated revenues decreased to **$156.8 million**, leading to a **$148.4 million** net loss, significantly impacted by a one-time convertible note exchange expense [Consolidated Financials](index=2&type=section&id=Consolidated%20Financials) Q2 2025 consolidated revenue decreased to **$156.8 million**, with net loss widening to **$148.4 million** due to a one-time convertible note exchange expense Q2 2025 Consolidated Financial Performance (vs. Q2 2024) | Metric | Q2 2025 | Q2 2024 | | :--- | :--- | :--- | | Total Revenues (in millions) | $156.8 | $182.2 | | Operating Loss (in millions) | $60.0 | $61.7 | | Net Loss (in millions) | $148.4 | $10.3 | | Loss Per Share (in dollars) | $0.19 | $0.01 | - The net loss in Q2 2025 was significantly impacted by a **$91.7 million** non-recurring expense related to a convertible note exchange that closed on April 1, 2025[3](index=3&type=chunk) - The prior-year period (Q2 2024) included a **$60.5 million** unrealized gain in the fair value of GeneDx Holdings Corp., which contributed to the lower net loss in that quarter[3](index=3&type=chunk) [Segment Performance](index=3&type=section&id=Segment%20Performance) Pharmaceuticals segment revenue slightly increased to **$55.7 million**, while Diagnostics revenue decreased to **$101.1 million** due to asset sales, though its operating loss narrowed Pharmaceuticals Segment Performance (Q2 2025 vs. Q2 2024) | Metric | Q2 2025 | Q2 2024 | | :--- | :--- | :--- | | Revenue from products (in millions) | $40.7 | $40.5 | | Revenue from IP & other (in millions) | $15.0 | $12.3 | | **Total Revenue (in millions)** | **$55.7** | **$52.8** | | Operating Loss (in millions) | $28.7 | $24.8 | Diagnostics Segment Performance (Q2 2025 vs. Q2 2024) | Metric | Q2 2025 | Q2 2024 | | :--- | :--- | :--- | | Revenue from services (in millions) | $101.1 | $129.4 | | Operating Loss (in millions) | $18.2 | $26.6 | - The decrease in Diagnostics revenue was primarily due to lower clinical test volume resulting from the sale of certain BioReference assets[7](index=7&type=chunk) [Financial Position and Corporate Actions](index=2&type=section&id=Financial%20Position%20and%20Corporate%20Actions) OPKO held **$285.4 million** in cash, exchanged **$159.2 million** in convertible notes, and authorized an additional **$100 million** for its stock repurchase program - Cash, cash equivalents, and restricted cash stood at **$285.4 million** as of June 30, 2025[7](index=7&type=chunk) - In Q2 2025, OPKO exchanged **$159.2 million** of outstanding convertible notes for **121.4 million shares** of common stock and approximately **$63.5 million** in cash[7](index=7&type=chunk) - The Board of Directors authorized an additional **$100 million** for its common stock repurchase program, increasing the total capacity to **$200 million**. As of June 30, 2025, **$58.5 million** had been repurchased[4](index=4&type=chunk) [Financial Statements](index=6&type=section&id=Financial%20Statements) The condensed consolidated financial statements detail OPKO Health's financial position as of June 30, 2025, with total assets of **$1,973.0 million** and total liabilities of **$676.1 million**, alongside operational results [Condensed Consolidated Balance Sheets](index=6&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) As of June 30, 2025, OPKO Health's total assets were **$1,973.0 million**, with total liabilities decreasing to **$676.1 million** due to reduced convertible notes Condensed Consolidated Balance Sheet Highlights (in millions) | Account | June 30, 2025 | Dec 31, 2024 | | :--- | :--- | :--- | | Cash and cash equivalents | $271.7 | $431.9 | | Total current assets | $583.3 | $662.1 | | **Total Assets** | **$1,973.0** | **$2,200.2** | | Total current liabilities | $171.2 | $193.1 | | Long-term portion of convertible notes | $80.5 | $173.6 | | **Total Liabilities** | **$676.1** | **$834.8** | | **Total Equity** | **$1,296.9** | **$1,365.4** | [Condensed Consolidated Statements of Operations](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) For Q2 2025, OPKO reported total revenues of **$156.8 million** and a net loss of **$148.4 million**, with six-month revenues at **$306.8 million** and a net loss of **$216.1 million** Condensed Consolidated Statement of Operations (in millions) | Metric | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | | :--- | :--- | :--- | | Total revenues | $156.8 | $182.2 | | Total costs and expenses | $216.8 | $243.9 | | Operating loss | $(60.0) | $(61.7) | | Other income (expense), net | $(102.5) | $51.1 | | **Net loss** | **$(148.4)** | **$(10.3)** | Condensed Consolidated Statement of Operations (in millions) | Metric | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | | Total revenues | $306.8 | $355.9 | | Operating loss | $(127.1) | $(133.1) | | **Net loss** | **$(216.1)** | **$(92.1)** |

Core Insights - OPKO Health, Inc. reported its business highlights and financial results for Q2 2025, indicating ongoing advancements in its clinical trials and product development [1][5]. Business Highlights - Merck is advancing a Phase 1 trial for an Epstein-Barr virus vaccine in collaboration with OPKO, evaluating safety and tolerability in 200 healthy adults [1]. - ModeX is progressing its immuno-oncology and immunology portfolio, with multiple clinical candidates, including MDX2001, which is in Phase 1 trials [1]. - OPKO presented promising preclinical data for OPK-88006, a dual agonist for treating metabolic disorders, showing superior therapeutic benefits compared to competitors [1]. - The FDA approved a supplemental application for the 4KScore® Test, allowing it to be performed without digital rectal examination information, enhancing its accessibility for prostate cancer assessment [1]. Financial Results - Total revenues for Q2 2025 were $156.8 million, down from $182.2 million in Q2 2024, with a net loss of $148.4 million, or $0.19 per share, compared to a net loss of $10.3 million, or $0.01 per share, in the prior year [5][13]. - Revenue from product sales was $40.7 million, slightly up from $40.5 million in Q2 2024, while revenue from services decreased to $101.1 million from $129.4 million [5][13]. - The company authorized an additional $100 million for its stock repurchase program, bringing the total capacity to $200 million, representing approximately 14% of OPKO's common shares outstanding [2]. Cash and Assets - As of June 30, 2025, OPKO had cash, cash equivalents, and restricted cash totaling $285.4 million [5]. - The company completed an exchange agreement to purchase $159.2 million of outstanding convertible notes for shares and cash [5].

Core Viewpoint - Entera Bio Ltd. has received FDA agreement to support the NDA marketing application filing for EB613 based on a single 24-month phase 3 study, marking a significant regulatory milestone for the company and the osteoporosis community [1][2] Company Overview - Entera Bio is focused on developing oral peptide and protein replacement therapies, leveraging its proprietary N-Tab™ technology platform [5] - The company's lead product candidate, EB613, is an oral anabolic treatment for post-menopausal women with low bone mineral density (BMD) and high-risk osteoporosis [5] Product Development - EB613 is designed as the first oral, once-daily anabolic tablet treatment for osteoporosis, aiming to increase skeletal mass, improve bone microarchitecture, and reduce fracture risk [3][4] - A phase 2 study of EB613 demonstrated significant efficacy, meeting all biomarker and BMD endpoints without major safety concerns [4] Regulatory Context - The FDA's agreement allows Entera to advance its clinical development program without waiting for the qualification of the SABRE initiative, which aims to establish BMD as a regulatory endpoint [2][6] - The SABRE initiative has shown that treatment-related gains in total-hip BMD can predict fracture-risk reduction, with a correlation coefficient of 0.73 [6] Market Need - Osteoporosis affects over 200 million women globally, with a significant portion remaining undertreated despite available injectable treatments [3] - The lack of new FDA-approved osteoporosis drugs since 2019 highlights the urgent need for innovative treatments like EB613 [3]

Core Viewpoint - OPKO Health, Inc. is set to report its operating and financial results for the second quarter and first half of 2025 on July 31, 2025, after U.S. market close [1] Group 1: Financial Reporting - The financial results will cover the three and six months ended June 30, 2025 [1] - A conference call and live audio webcast will be held on July 31 at 4:30 p.m. Eastern time to discuss the results and provide financial guidance [1] Group 2: Conference Call Information - Participants are encouraged to pre-register for the conference call to receive a unique PIN for immediate access [2] - Those unable to pre-register can join by dialing specific numbers for U.S. and international participants [2] Group 3: Replay Information - A telephone replay of the conference call will be available until August 7, 2025, with specific dialing instructions provided [3] - A webcast replay will be accessible approximately one hour after the live call [3] Group 4: Company Overview - OPKO Health is a multinational biopharmaceutical and diagnostics company focused on establishing leading positions in rapidly growing markets through its expertise and proprietary technologies [4]

Core Insights - OPKO Health and Entera Bio announced a first-in-class oral GLP-2 analog for treating Short Bowel Syndrome (SBS), selected for a poster presentation at the ESPEN Congress in September 2025 [1][2] Company Overview - OPKO Health is a multinational biopharmaceutical and diagnostics company focused on establishing industry-leading positions in rapidly growing markets through its discovery, development, and commercialization expertise [6] - Entera Bio is a clinical-stage company developing oral peptide and protein replacement therapies, leveraging its proprietary N-Tab™ technology for significant unmet medical needs [5] Product Development - The oral GLP-2 tablet program combines OPKO's long-acting GLP-2 agonist with Entera's N-Tab™ technology, aimed at patients with SBS and related gastrointestinal disorders [2] - Current approved therapy for SBS, GATTEX (teduglutide), generates approximately $800 million in annual sales and requires daily subcutaneous injections [4] Market Context - Short Bowel Syndrome affects around 30,000 patients in the US and EU, leading to malabsorption and increased risk of malnutrition [4] - The introduction of an oral tablet format for GLP-2 therapy may improve patient compliance and enable personalized treatment [3]

Group 1 - OPKO Health, Inc. announced its participation in the 3rd Annual Piper Sandler Obesity Symposium, which will be held virtually on June 26, 2025 [1] - Management will engage in a fireside discussion moderated by Edward Tentoff, a Managing Director and Senior Biotechnology Analyst [1] - Investors interested in the symposium can register by contacting their Piper Sandler representative [1] Group 2 - OPKO Health is a multinational biopharmaceutical and diagnostics company focused on establishing industry-leading positions in large, rapidly growing markets [2] - The company leverages its expertise in discovery, development, and commercialization, along with novel and proprietary technologies [2]

Core Viewpoint - OPKO Health and Entera Bio are advancing the development of an oral treatment, OPK-88006, for obesity and metabolic disorders, with new pharmacologic data to be presented at the ENDO 2025 annual meeting [1][2]. Company Overview - OPKO Health is a multinational biopharmaceutical and diagnostics company focused on establishing leading positions in rapidly growing markets through its discovery, development, and commercialization expertise [5]. - Entera Bio is a clinical-stage company developing oral peptide and protein replacement therapies, leveraging its proprietary N-Tab™ technology to address significant unmet medical needs [4]. Product Development - OPK-88006 is a dual agonist GLP-1/glucagon peptide being developed as both a once-daily oral tablet and a weekly injectable treatment [2][3]. - The oral formulation aims to provide a simpler titration process and improved tolerability for patients, with a focus on sustainable weight loss to mitigate comorbidities like severe fatty liver and sleep apnea [3]. - Both companies plan to file an Investigational New Drug application with the U.S. FDA for OPK-88006 later this year, with Phase 1 clinical studies in preparation [3]. Clinical Trials and Research - The upcoming presentation at the ENDO 2025 meeting will showcase in vivo pharmacokinetic and pharmacodynamic results for OPK-88006 [4]. - Entera's advanced product candidate, EB613, is also in development as the first oral treatment for post-menopausal women with low bone mineral density and high-risk osteoporosis, with a Phase 2 study already meeting its endpoints [4].

Core Insights - ModeX Therapeutics Inc., a subsidiary of OPKO Health, has established a Scientific Advisory Board to enhance its immunology and oncology pipeline, focusing on multispecific antibodies and vaccines [1][3][9] - The board consists of prominent scientists recognized for their contributions to biomedical research and therapeutic advancements [2][4][5] Company Overview - ModeX is a clinical-stage biopharmaceutical company developing proprietary multispecific therapeutics using its MSTAR platform, which allows for the creation of antibodies that can target four or more disease pathways [9] - The company is focused on addressing complex diseases, including various forms of cancer and immune-mediated diseases, with a promising pipeline of first-in-class drugs [1][8][9] Scientific Advisory Board - The founding members of the board include Drs. John Heymach, Ronald Levy, Myron Cohen, and Rafi Ahmed, all of whom are leaders in their respective fields [2][4][6] - The board aims to guide ModeX in advancing next-generation immune therapies that can target multiple disease pathways simultaneously [3][5] Multispecific Therapeutics - Multispecific therapeutics are positioned as the future of medicine, addressing the limitations of traditional single-target therapies by combining multiple biological targets [8] - ModeX's approach aims to revolutionize treatment options for patients suffering from complex and previously untreatable conditions [8][9]

Summary of OPKO Health Conference Call Company Overview - **Company**: OPKO Health - **Founded**: 1991 by Phil Frost - **Business Segments**: - Pharmaceutical business with revenue in Latin America and the U.S. (Engenla, a growth hormone product partnered with Pfizer) - Diagnostic services including the BioReference laboratory, one of the top 10 labs in the U.S. - Pharmaceutical discovery through Modex Therapeutics, focusing on multi-specific antibodies and vaccine platforms [3][4][5] Recent Developments - **Sale to LabCorp**: - Announced a second sale of oncology-related diagnostics for $192.5 million upfront, with an additional potential earn-out of $32.5 million [6][7] - The sale aims to streamline operations and enhance profitability, focusing on the core profitable areas in New York and New Jersey [8][9] Financial Performance - **Revenue Insights**: - The company reported $520 million in revenue, with $300 million from core operations in New York and New Jersey [7][8] - The remaining diagnostics business is expected to be profitable starting now and through 2025, driven by consolidation efforts and high-margin tests [9][10] - **Valuation Multiples**: - The company anticipates trading multiples for the remaining diagnostics business to be in the range of 2 to 3 times revenue [12][13] Growth Hormone Collaboration with Pfizer - **Revenue Shortfall**: - Reported $4.5 million in revenue for the growth hormone product Anjenla, lower than the expected $9.6 million due to higher copay assistance costs [16][17] - **Future Expectations**: - Pfizer estimates Anjenla could reach $500 million to $1 billion in peak sales, with OPKO's profit share expected to grow to the mid-20% range as the franchise expands [19][20] Modex Therapeutics Updates - **Clinical Trials**: - Plans to show clinical safety updates for a tetra-specific antibody by the end of 2025, with ongoing trials focusing on specific cancer targets [22][24] - The partnership with Merck for an EBV vaccine is progressing well, with a milestone payment expected upon moving to phase two [27][49] Pipeline and Future Programs - **New Drug Developments**: - Introduction of a dual GLP-1/glucagon agonist for obesity and NASH, with an IND expected later this year [58][60] - The drug aims to differentiate itself by having direct action on the liver and promoting anti-fibrotic effects [59][62] Financial Position and Cash Runway - **Cash Reserves**: - Ended the first quarter with approximately $450 million in cash, excluding the expected $192 million from LabCorp [76][77] - **Use of Funds**: - Plans to allocate $100 million for R&D and another $100 million for stock buybacks [76][77] Government Funding - **BARDA Funding**: - Received $59 million last year and $51 million this year for developing multi-specific antibodies against COVID and flu, which significantly supports R&D budgets [80][81] Regulatory Interactions - **FDA Engagement**: - Positive interactions with the FDA regarding COVID programs, with timely responses and no significant delays reported [82] This summary encapsulates the key points discussed during the OPKO Health conference call, highlighting the company's strategic direction, financial performance, and future growth prospects.